Results 11 to 20 of about 66,662 (177)
Orphanet Journal of Rare Diseases, 2021 Background Patients with lymphangioleiomyomatosis (LAM) frequently experience pneumothorax. Although sirolimus is the standard therapy for LAM, its effect on pneumothorax is controversial.
Teiko Sakurai +8 more
doaj +1 more source
Pharmaceutics, 2021 Sirolimus is widely used in transplantation, where its therapeutic drug monitoring (TDM) is well established. Evidence of a crucial role for sirolimus in the PI3K/AkT/mTor pathway has stimulated interest in its involvement in neoplasia, either as ...
Amelia-Naomi Sabo +5 more
doaj +1 more source
Molecules, 2015 The present study aimed to investigate the effect of Eudragit® E/HCl (E-SD) on the degradation of sirolimus in simulated gastric fluid (pH 1.2) and to develop a new oral formulation of sirolimus using E-SD solid dispersions to enhance oral ...
Youngseok Cho +5 more
doaj +1 more source
Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review
Acta Dermato-Venereologica, 2019 Vascular anomalies (VAs) may be associated with significant morbidity and mortality. The aim of this study was to evaluate the efficacy and safety of sirolimus (rapamycin) in the treatment of children and young adults with complicated VAs.
Shira Sandbank +4 more
doaj +1 more source
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
CAQ Corner: Immune‐mediated complications
, 2022 Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley +1 more source
Journal of Lipid Research, 2002 Sirolimus (Rapammune®, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment, and frequently leads to cardiovascular disease.
Joel D. Morrisett +9 more
doaj +1 more source
Frontiers in Pharmacology, 2021 The purposes of this study were to explore the population pharmacokinetics and initial dose optimization of sirolimus improving drug blood level for seizure control in pediatric patients with tuberous sclerosis complex (TSC).
Xiao Chen +10 more
doaj +1 more source
Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis. [PDF]
PLoS ONE, 2013 We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC).
Izabela A Malinowska +12 more
doaj +1 more source
Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
Frontiers in Pharmacology, 2021 Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a ...
Xiao Chen +8 more
doaj +1 more source